Literature DB >> 11484068

Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential.

J Cheng1, K Kamiya, I Kodama.   

Abstract

Carvedilol is a unique cardiovascular drug of multifaceted therapeutic potential. Its major molecular targets recognized to date are membrane adrenoceptors (beta 1, beta 2, and alpha 1), reactive oxygen species, and ion channels (K+ and Ca2+). Carvedilol provides prominent hemodynamic benefits mainly through a balanced adrenoceptor blockade, which causes a reduction in cardiac work in association with peripheral vasodilation. This drug assures remarkable cardiovascular protection through its antiproliferative/atherogenic, antiischemic, antihypertrophic, and antiarrhythmic actions. These actions are a consequence of its potent antioxidant effects, amelioration of glucose/lipid metabolism, modulation of neurohumoral factors, and modulation of cardiac electrophysiologic properties. The usefulness of carvedilol in the treatment of hypertension, ischemic heart disease, and congestive heart failure is based on a combination of hemodynamic benefits and cardiovascular protection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11484068     DOI: 10.1111/j.1527-3466.2001.tb00061.x

Source DB:  PubMed          Journal:  Cardiovasc Drug Rev        ISSN: 0897-5957


  14 in total

1.  Palladium(0)-catalyzed intermolecular amination of unactivated C(sp³)-H bonds.

Authors:  Jun Pan; Mingjuan Su; Stephen L Buchwald
Journal:  Angew Chem Int Ed Engl       Date:  2011-08-02       Impact factor: 15.336

Review 2.  Molecular and cellular basis of viable dysfunctional myocardium.

Authors:  Marina Bayeva; Konrad Teodor Sawicki; Javed Butler; Mihai Gheorghiade; Hossein Ardehali
Journal:  Circ Heart Fail       Date:  2014-07       Impact factor: 8.790

Review 3.  Mitochondria and cardiovascular diseases-from pathophysiology to treatment.

Authors:  Gerasimos Siasos; Vasiliki Tsigkou; Marinos Kosmopoulos; Dimosthenis Theodosiadis; Spyridon Simantiris; Nikoletta Maria Tagkou; Athina Tsimpiktsioglou; Panagiota K Stampouloglou; Evangelos Oikonomou; Konstantinos Mourouzis; Anastasios Philippou; Manolis Vavuranakis; Christodoulos Stefanadis; Dimitris Tousoulis; Athanasios G Papavassiliou
Journal:  Ann Transl Med       Date:  2018-06

4.  The Results of ACES (Antihypertensive Combinations' Long Term Efficacy Comparing Study): Analysis of Metabolic Effects of Antihypertensive Combination Therapies.

Authors:  Zoltán Nádházi; Csaba András Dézsi
Journal:  Clin Drug Investig       Date:  2016-10       Impact factor: 2.859

Review 5.  Mitochondria-targeted agents: Future perspectives of mitochondrial pharmaceutics in cardiovascular diseases.

Authors:  Thekkuttuparambil Ananthanarayanan Ajith; Thankamani Gopinathan Jayakumar
Journal:  World J Cardiol       Date:  2014-10-26

Review 6.  Doxorubicin-Induced Cardiomyopathy in Children.

Authors:  Trevi R Mancilla; Brian Iskra; Gregory J Aune
Journal:  Compr Physiol       Date:  2019-06-12       Impact factor: 9.090

7.  Managing cardiotoxicity of chemotherapy.

Authors:  Alessandro Colombo; Carlo A Meroni; Carlo M Cipolla; Daniela Cardinale
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-08

Review 8.  Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.

Authors:  Jing Zhang; Xiaohai Cui; Yan Yan; Min Li; Ya Yang; Jiansheng Wang; Jia Zhang
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

9.  Breast Cancer Survivorship and Cardiovascular Disease: Emerging Approaches in Cardio-Oncology.

Authors:  Yu Xie; William J Collins; M William Audeh; Stephen L Shiao; Roberta A Gottlieb; Marc T Goodman; C Noel Bairey Merz; Puja K Mehta
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-12

10.  The Use of Cardiac Resynchronization Therapy in Cancer Patients with Heart Failure.

Authors:  Anecita P Fadol; Elie Mouhayar; Cielito C Reyes-Gibby
Journal:  J Clin Exp Res Cardiol       Date:  2017-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.